Every 8-K that ANAPTYSBIO INC (ANABV) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow ANABV and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ANABV filings page.
AnaptysBio, Inc. is providing tax information to its stockholders about the dividend they received from the separation and spin-off of First Tracks Biotherapeutics, Inc. The company has filed IRS Form 8937 and is making the same information available in the Investors section of its website.
The Form 8937 explains how the spin-off dividend is treated for tax purposes and how stockholders should determine their adjusted tax basis. AnaptysBio emphasizes that this material is for informational purposes only and urges stockholders to consult their own tax advisors about their specific situations.
AnaptysBio, Inc. is changing its fiscal year-end from December 31 to June 30, as approved by its board of directors on May 18, 2026. The next fiscal year will begin on July 1, 2026.
The company will file a transition Form 10-KT covering the six-month period from January 1, 2026 through June 30, 2026, then begin filing quarterly reports based on the new fiscal year, starting with the quarter ending September 30, 2026.
AnaptysBio, Inc. appointed Christopher M. Murphy as Chief Financial Officer effective May 11, 2026, serving as an independent contractor under a consulting agreement. He will receive monthly consulting fees of $42,916.66, an annual target cash bonus opportunity of up to 40% of total annual consulting fees, and an equity grant valued at $1,750,000 in restricted stock units vesting over four years.
If the agreement is terminated without cause, he is eligible for nine months of continued fees, or twelve months plus bonus-related payments and full vesting of equity awards if this occurs in connection with a qualifying corporate transaction. The Board also appointed Owen Hughes as a Class I director effective May 11, 2026, with an initial grant of 11,250 restricted stock units vesting over three years.
AnaptysBio, Inc. completed the spin-off of its biopharma operations into First Tracks Biotherapeutics, Inc. on April 20, 2026 and is now providing unaudited pro forma financial information reflecting the company after this separation.
The pro forma balance sheet as of December 31, 2025 shows a $100.0 million initial cash distribution to First Tracks, reducing AnaptysBio’s cash and cash equivalents from $238,196 to $138,196 (in thousands). Pro forma 2025 results convert a historical net loss of $13,232 (in thousands) into net income of $114,857 (in thousands), with collaboration revenue of $234,603 (in thousands) and basic pro forma earnings per share of $3.99.
Notes explain that First Tracks is treated as discontinued operations under ASC 205, that AnaptysBio anticipates approximately $7.0 million of additional non-recurring spin-off costs, and that a transition services agreement will add about $2.0 million to general and administrative expenses.
AnaptysBio, Inc. completed the spin-off of its former biopharma operations into First Tracks Biotherapeutics, creating a focused royalty management company. Shareholders received one share of First Tracks common stock for every one share of AnaptysBio common stock held on the April 6, 2026 record date. First Tracks now trades on Nasdaq under “TRAX,” while AnaptysBio continues under “ANAB.”
Post-spin, AnaptysBio retains the royalty management business, exclusively overseeing financial collaborations for Jemperli with GSK and imsidolimab with Vanda. Management highlights a virtual model with limited staff, minimal operating expenses and a targeted greater than 95% EBIT margin. The parties entered into a detailed Separation and Distribution Agreement and a Transition Services Agreement governing asset and liability allocations, shared IP, tax matters and up to two years of transition services. The spin-off also triggered board resignations and executive transitions, including the Chief Medical Officer moving to First Tracks and the CEO serving AnaptysBio via a consulting agreement.